# **Experience the many layers** of Advantage Multi for Cats

(imidacloprid+moxidectin)





## Fleas don't have to bite to die

The imidacloprid in Advantage Multi® for Cats (imidacloprid + moxidectin) spreads across the skin and coat to kill fleas through contact



The only prescription flea control product that does not require fleas to bite and take a blood meal

A study showed >97% efficacy all month long<sup>4</sup>





Treats and controls ear mites – the #1 cause of otitis externa in cats.

Advantage Multi® for Cats is the only FDA-approved product indicated for ferrets for the treatment of fleas and prevention of heartworm disease.‡

<sup>\*</sup>Three in vivo experiments were conducted to evaluate the effect of Advantage® Topical Solution (imidacloprid) on fleas (Ctenocephalides felis). A total of seven (7) dogs were treated with Advantage® Topical Solution. Seven (7) days after application, areas on the dogs were shaved to allow visual observation. A petri dish was attached over each spot, and then infested with up to 100 fleas. In all replicates, the fleas stopped their feeding activity and started tetanic trembling movements within 3–5 minutes. In one hour, all fleas were dead. <sup>1-3</sup> †Advantage Multi® for Cats (imidacloprid + moxidectin) (0.4 mL) is indicated for ferrets that weigh at least 2 lbs.



# Administering oral medications can sometimes be a struggle for cat owners

Advantage Multi® for Cats (imidacloprid + moxidectin) is a monthly transdermal solution that provides broad-spectrum protection against fleas, intestinal worms, heartworm disease and even ear mites.

And because it's in an easy-to-apply, transdermal form, Advantage Multi® provides an additional layer of owner convenience and compliance.


## The power of a transdermal formulation

Advantage Multi® is a transdermal solution that gets the most out of each active ingredient.

Moxidectin quickly absorbs through the skin into the subcutaneous fat and bloodstream, disseminating throughout the body

Imidacloprid spreads over the skin and coat, where it resides in the waterproof lipid layer, hair follicles and sebaceous (oil) glands

After just four doses of Advantage Multi<sup>o</sup>, cats achieve steady-state serum levels.<sup>5</sup>



Kills multiple life stages of intestinal parasites

## **Broad-spectrum IP coverage**

Most intestinal parasiticides only cover adult worms.\*

Advantage Multi® for Cats goes broad and deep to protect cats from multiple life stages of the most common IPs.



## **Hookworms**

A. tubaeforme L4

A. tubaeforme immature adults

A. tubaeforme adults



## **Roundworms**

T. cati L4

T. cati adults



























Based on label comparisons for intestinal parasites.



# Unique heartworm prevention for a unique disease

## Transdermal moxidectin has an extended half-life\*

When applied transdermally, moxidectin concentrates in the fatty tissue, slowly releasing into the bloodstream, resulting in a long half-life.



Indoor-only cats are still at risk for heartworm disease




In a study of 50 cases, 27% of cats with heartworm disease were found to be indoor-only cats<sup>9</sup>

## Backward and forward† protection

Like all heartworm prevention products, Advantage Multi® works backward to kill heartworm larvae after an infection has already been established in the cat from the previous month.

It also works forward† to prevent the establishment of an infection by killing newly acquired heartworm larvae all day, every day, for the next month.<sup>10</sup>





## for cats

(imidacloprid+moxidectin)

## Protect your feline patients from fleas, ear mites, intestinal worms\* and heartworm disease with the many layers of Advantage Multi® for Cats

(imidacloprid + moxidectin)



advantage multi®
for cats
(imidacloprid+moxidectin)

Cat 5 2-5 lbs. **Cat 9** 5.1-9 lbs.

**Cat 18** 9.1–18 lbs.

# Order today. Contact your Bayer Sales Representative or Customer Service at (800) 633-3796.

- \*Treats and controls hookworms and roundworms in cats
- <sup>1</sup> Mehlhorn H, Hansen O, Mencke N. (2001). Comparative study on the effects of three insecticides (fipronil, imidacloprid, selamectin) on developmental stages of the cat flea (*Ctenocephalides felis* Bouché 1835): a light and electron microscopic analysis of *in vivo* and *in vitro* experiments. *Parasitol* Res. 87(3):198-207.
- <sup>2</sup> Mehlhorn H. (2000). Mode of action of imidacloprid and comparison with other insecticides (i.e., fipronil and selamectin) during *in vivo* and *in vitro* experiments. *Suppl Compend Contin Educ Pract Vet*. 22(4A):4-8.
- <sup>3</sup> Mehlhorn H, Mencke N, Hansen O. (1999). Effects of imidacloprid on adult and larval stages of the flea Ctenocephalides felis after in vivo and in vitro applications: a light- and electron-microscopy study. Parasital Res. 85(8-9):625-637
- <sup>4</sup> Freedom of Information Summary, NADA: 141-254
- <sup>5</sup> Little S, Hostetler J, Thomas J, et al. (2015). Moxidectin steady state prior to inoculation protects cats from subsequent, repeated infection with *Dirofilaria immitis. Parasit Vectors* 8:107. DOI:10.1186/s13071-015-0710-7
- <sup>6</sup> Kvaternicka V, Kellermann M, Knaus M, et al. (2014). Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene eprinomectin and praziguantel. *Vet Parasitol*. 202:2–9.
- <sup>7</sup> Sarasola P, Jernigan AD, Walker DK, et al. (2002). Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. *J Vet Pharmacol Therap.* 25(4):265–272.
- <sup>8</sup> Data on file Bayer Shawnee Mission KS
- 9 Atkins CE, DeFrancesco TC, Coates JR, et al. (2000). Heartworm infection in cats: 50 cases (1985–1997). J Am Vet Med Assoc. 217(3):355–358.
- <sup>10</sup> Bowman DD, Ohmes CM, Bradford M, et al. (2018). Efficacy of Advantage Multi® for Cats for the prevention of heartworm disease and infection all month long. In: *Proceedings*. American Association of Veterinary Parasitologists. 63rd Annual Meeting. July 14–17, 2018. Denver, CO.





## **ADVANTAGE MULTI®**

## (imidacloprid + moxidectin) Topical Solution

Once-a-month topical solution for cats for the prevention of heartworm disease, kills adult fleas, is indicated for the treatment of flea infestations, as well as the treatment and control of ear mite infestations and intestinal parasite infections in cats and kittens 9 weeks of age and older and that weigh at least 2 lbs.

Once-a-month topical solution for ferrets for the prevention of heartworm disease, kills adult fleas, and is indicated for the treatment of flea infestations. Indicated for ferrets that weigh at least 2 lbs.

CAUTION:

(U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian

DESCRIPTION:

Advantage Multi® for Cats (10% imidacloprid + 1% moxidectin) is a colorless to yellow ready-to-use solution packaged in single-dose applicator tubes for topical treatment of cats. The formulation and dosage schedule are designed to provide a minimum of 4.5 mg/lb (1.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin based on body weight. Imidacloprid is a chloronicotinyl nitroguanidine insecticide. The chemical name of imidacloprid is 1-[(6-Chloro-3-pyridinyl)-nethyl]-N-nitro-2-imidazolidinimine. Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycetes *Screptomycetes cyaneogriseus* noncyanogenus. The chemical name of moxidectin is [6R, 23E, 25S(E)]-5-0-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

INDICATIONS:

Advantage Multi for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. Advantage Multi for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. Advantage Multi for Cats is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites:

		Intestinal Stage		
Intestinal Parasite		Adult	Immature Adult	Fourth Stage Larvae
Hookworm Species	Ancylostoma tubaeforme	Х	Х	Х
Roundworm Species	Toxocara cati	Х		Х

WARNINGS:
Do not use on sick, debilitated, or underweight cats (See ADVERSE REACTIONS).

Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.

HUMAN WARNINGS:

Not for human use. Keep out of the reach of children.

Children should not come in contact with the application site for 30 minutes after application.

Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, ingiling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling. If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersoritivity to benzyl alcohol, imidacloprid, or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Bayer Veterinary Services at 1-800-422-9874. For consumer questions call 1-800-255-6826.

1-800-2-50-50-2.0.

PRECAUTIONS:
Do not dispense dose applicator tubes without complete safety and administration information.

Avoid oral ingestion. Cats may experience hypersalivation, tremors, vomiting and decreased appetite if Advantage Multi for Cats is inadvertently administered orally or through grooming/licking of the application site.

The safety of Advantage Multi for Cats has not been established in breeding, pregnant, or lactating cats.

The effectiveness of Advantage Multi for Cats against heartworm infections (D. immitis) after bathing has not been evaluated in the properties of the pr

in cats.

Use of this product in geriatric patients with subclinical conditions has not been adequately studied. Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using this drug (See ADVERSE REACTIONS).

## ADVERSE REACTIONS:

ving treatment with Advantage Multi for Cats or an active control, cat owners reported the following post-

OBSERVATION	Advantage Multi n=113	Active Control n=38
Lethargy (protracted sleeping, poorly responsive )	3 cats* (2.7%)	None observed
Behavioral changes (e.g., agitated, excessive grooming, hiding, pacing, spinning)	9 cats (8.0%)	1 cat (2.6%)
Discomfort (e.g., scratching, rubbing, head-shaking)	5 cats (4.4%)	None observed
Hypersalivation (within 1 hour after treatment)	3 cats (2.7%)	None observed
Polydipsia	3 cats (2.7%)	None observed
Coughing and gagging	1 cat (0.9%)	None observed

\*These three cats were from the same household and included one 13-yr-old cat in good health, one 15-yr-old FIV positive cat in good health, and one 15-yr-old, underweight cat in fair health. Lethargy was noted for 24 to 36 hrs after the first treatment only; one cat was unsteady at 48 hrs. These cats were not on other medications.

During another field study, a 16-year-old cat with renal disease slept in the same place without moving for two days following application. (See PRECAUTIONS).

During another field study, a 16-year-old cat with renal disease slept in the same place without moving for two days following application. (See PRECAUTIONS).

Laboratory Effectiveness Studies: Advantage Multi for Cats was administered at the recommended dose to 215 cats in 20 effectiveness studies. One random-sourced cat exhibited signs consistent with either moxidectin toxicity or viral respiratory disease and died 26 hours after product application; necropsy findings were inconclusive as to the ause of death. A second cat that became ill 3 days after application of Advantage Multi for Cats responded to treatment for respiratory infection and completed the study. A third cat became ill on day 3 and died with signs and lesions attributable to panleukopenia on day 7 after moxidectin application.

Post-Approval Experience: The following adverse events are based on postapproval adverse drug experience reporting. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events in cats are listed in decreasing order of reporting frequency: hypersalivation, depression/tethargy, application site reactions (alopecia, purritus, lesions, and erythema), decreased appetite, vomiting, hyperactivity, ataxia, trembling, and behavior disorder (hiding). In some cases death has been reported. In humans, ocular and dermal irritation, nausea, numbness or tingling of the mouth and lips, anaphylaxis, pruritus, vomiting, and tongue/taste abnormalities have been reported following exposure to this product. To report suspected adverse events and/or obtain a copy of the SDS or for technical assistance, call Bayer Animal Heath at 1-800-422-9874. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/Animal/Veterinary/SafetyHealth.

## DOSAGE AND ADMINISTRATION:

The recommended minimum dos month, by topical administration. Do not apply to irritated skin. se is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a

1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the Advantage Multi® for Cate tube that correctly corresponds with the body weight of the cat.

of the Advantage With the Cats tube that correctly corresponds with the body weight of the cat.					
Cat (lbs.)	Advantage Multi for Cats	Volume (mL)	lmidacloprid (mg)	Moxidectin (mg)	
2-5	Advantage Multi 5	0.23	23	2.3	
5.1-9	Advantage Multi 9	0.4	40	4	
9.1-18*	Advantage Multi 18	0.8	80	8	

- \* Cats over 18 lbs. should be treated with the appropriate combination of Advantage Multi for Cats tubes
- While holding the tube in an upright position, remove the cap from the tube.

   Turn the cap over and push the other end of cap onto the tip of the tube.
- 4. Twist the cap to break the seal and then remove cap from the tube.



4. Twist the cap to break the seal and then remove cap from the tube.

5. Part the hair on the back of the cat's neck at the base of the head, until the skin is visible. Place the tip of the tube on the skin and apply the entire contents directly on the exposed skin. Lift tube away from skin before releasing pressure on tube.

Do not get this product in the cat's mouth or eyes or allow the cat to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site.

Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some cats. This is temporary and does not affect the safety and effectiveness of the product. Heartworm Prevention: For prevention of heartworm disease, Advantage Multi for Cats should be administered at one-month intervals. Advantage Multi for Cats may be administered year-around or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer Advantage Multi for Cats immediately and resume the monthly dosing schedule. When replacing another heartworm preventiancy my mention program, the first treatment with Advantage Multi for Cats should be given within one month of the last dose of the former medication. At the discretion of the veterinarian, cats older than 6 months of age may be tested to determine the presence of existing heartworm infection before treatment with Advantage Multi for Cats (See ADVERSE REACTIONS - Post-Approval Experience).

Flea Treatment: For the treatment of flea infestations, Advantage Multi for Cats should be administered at one-month intervals. If the cat is already infested with fleas when the first dose of Advantage Multi for Cats should be administered and the adm

The provided in the cast should be administered once as a single topical dose. Monthly use of Advantage Multi for Cats will control any subsequent ear mite infestations. Intestinal Nematode Treatment: For the treatment and control of intestinal hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults and fourth stage larvae) and roundworm infections caused by Ancylostoma and fourth stage larvae), Advantage Multi for Cats should be administered once as a single topical dose.

ANIMAL SAFETY:
Studies in Kittens: Advantage Multi for Cats was topically applied at 0, 1, 3, and 5X the maximum dose to 48 healthy 9-week-old kittens on days 0, 28, and 56. Lethargy was observed in 1 kitten from the 3X group and 1 from the 5X group on the day after initial treatment; the kitten from the 3X group was also disoriented and ataxic. One kitten from the 3X group had a slow pupillary light response two days after treatment and one had tremors the day after treatment. Hypersalivation was seen in one kitten from the 5X group approximately six hours post-treatment. One kitten from the 3X group was coratching at the treatment site 2 days after treatment. Slight cough was noted in 7 different kittens (2-0X, 2-1X, and 3-5X) during the 13-day period following the first treatment. Slight cough was noted in 7 different kittens (2-0X, 2-1X, and 3-5X) during the 13-day period following the first treatment. Histopathology showed granulomatous inflammation (1-5X) and lymphoid hyperplasia (2-1X, 4-3X) were seen in treated kittens. In a second study, Advantage Multi for Cats was topically applied at 0, 1.7, 5.2 and 8.7X the maximum dose to 48 healthy 9-week-old kittens every two weeks for 6 doses. One kitten in the 8.7X group apparently ingested an unknown amount of the drug and developed the following clinical signs prior to euthanasia: mydriasis, salivation, depression, vomiting, unsteadiness, rapid to slow to difficult breathing, poor pupillary response, generalized tremors, inability to move, and nystagmus. Two kittens in the 2.5X group developed mydriasis, salivation, depression, squinting, and poor appetite. A kitten in the 1.7X group developed mydriasis.

\*\*Dose Tolerance Study: Eight healthy juvenile cats were topically dosed with a single application of Advantage Multi for Cats was tested in case of accidental oral ingestion. The maximum topical dose was orally administered to twelve healthy 9-week-old kittens. Hypersalivation (8 of 12 kittens) and vomiting (12 of 12 kittens) were observed immediately post

Use only the 0.4 mL *Advantage Multi for Cats* in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8 mL size could result in an overdose.

## INDICATIONS:

For Ferrets:

Advantage Multi for Cats is indicated for the prevention of heartworm disease in ferrets caused by Dirofilaria immitis Advantage Multi for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

## WARNINGS:

on sick or debilitated ferrets.

### PRECAUTIONS:

Do not dispense dose applicator tubes without complete safety and administration information

The safety of Advantage Multi for Cats has not been established in breeding, pregnant, and lactating ferrets. Treatment of ferrets weighing less than 2.0 lbs (0.9 kg) should be based on a risk-benefit assessment. The effectiveness of Advantage Multi for Cats in ferrets weighing over 4.4 lbs. (2.0 kg) has not been established.

ADVERSE REACTIONS:
Field safety Study in Ferrets: Advantage Multi for Cats was topically administered to 131 client-owned ferrets at the recommended dose volume (0.4 mL). The ferrets ranged in age from 3 months to 7 years, and weighed between 0.5 and 1.86 kg (1.1 to 4.1 lbs). The dose of imidacloprid ranged between 2.15 and 80.2 mg/kg in this study. The dose of imidacloprid ranged between 2.15 and 80.2 mg/kg in this study. The dose of moxidectin ranged between 2.2 to 8.0 mg/kg in this study.

Adverse reactions in ferrets following treatment included: pruritus/scratching, scabbing, redness, wounds and inflammation at the treatment site; lethargy, and chemical odor. These adverse reactions resolved without additional therapy. Owners also reported stiffening of the hair at the treatment site, however, this is expected with application of a topical product and is not considered an adverse reaction.

Three human adverse reactions were reported. An owner's finger became red following skin contact with the product. One owner reported a headache caused by chemical odor of the product. One owner reported a tingling sensation of the lips after kissing the treatment site.

Foreign Market Experience: Because the following events were reported voluntarily during post-approval use of the product in foreign markets, it is not always possible to reliably establish a causal relationship to drug exposure. Adverse events reported in ferrets topically treated with 0.4 mL imidacloprid + moxidectin for cats included: malaise, vomiting, diarrhea, shaking, mydriasis, hypersalivation with abnormal neurologic signs, seizures, death, generalized hematoma of the body, and alopecia at the treatment site. Adverse reactions in humans included: burning, tingling, numbness, bad taste in the mouth, dizziness, and headache.

ANIMAL SAFETY:
Ferrets: Advantage Multi for Cats was topically applied at 5X the recommended dose volume to six healthy 9-month-old ferrets on Study Days 0, 14, 28, and 42. Because the weights of the ferrets in this study ranged from 2.0 to 4.0 lb (0.9 kg to 1.8 kg), ferrets received a range of doses from 51.0 to 106.9 mg/lb (112 to 235 mg/kg) of imidacloprid and 5 to 10.5 mg/lb (11 to 23 mg/kg) of moxidectin. The following abnormal clinical signs were reported during the study: wet, matted, and/or greasy appearance to the hair, shaking of the head and/or body, rubbing of dose site on cage, and shedding. Slight increases in phosphorous, potassium, aspartate aminotransferase (AST), and glucose were seen during the study, however, no clinical signs related to these bloodwork changes were reported.

Oral Safety Study: Advantage Multi for Cats was orally administered at the recommended dose volume (0.4 mL) to eight healthy ferrets on Study Day 0. Ferrets were 78 to 101 days old (11.1 to 1.4.4 weeks) and weighted between 1.1 to 1.8 b (0.5 to 0.8 kg) body weight on the day of dosing, resulting in doses ranges 22.0-36.8 mg/lb (43.8-10.mg/kg) mixalcoprid and 2.2-3.7 mg/lb (4.8-8.0 mg/kg) moxidectin. The following abnormal clinical signs were reported immediately following oral administration of Advantage Multi for Cats: vomiting (one ferret) and ataxia (two ferrets). All abnormalities resolved without treatment or supportive care.

treatment or supportive care

## DOSAGE AND ADMINISTRATION:

DUSANCE AND FORMING THAT IS IN THE PROPERTY OF THE PROPERTY OF

once a month, by topical administration.					
Ferret (lbs.)	Advantage Multi for Cats	Volume (mL)	lmidacloprid (mg)	Moxidectin (mg)	
2.0 - 4.4	Advantage Multi 9	0.4	40	4	

Only the 0.4 mL applicator tube volume (Advantage Multi 9) should be used on ferrets.

Do not apply to irritated skin.

- 1. Remove one dose applicator tube from the package. Administer the entire contents of the Advantage Multi for Cats tube (0.4 m.L).

  2. While holding the tube in an upright position, remove the cap from the tube.

  3. Turn the cap over and push the other end of cap onto the tip of the tube.


  4. Twist the cap to break the seal and then remove cap from the tube.

  5. Part the hair on the back of the ferral's pack at the base of

- the tube.

  5. Part the hair on the back of the ferret's neck at the base of the head, until the skin is visible. Place the tip of the tube on the skin and apply the entire contents directly on the exposed skin. Lift tube away from skin before releasing pressure on tube.

  Do not get this product in the ferret's mouth or eyes or allow the ferret to lick the application site for 30 minutes. Treatment at the base of the head will minimize the opportunity for ingestion by grooming. In households with multiple pets, keep animals separated to prevent licking of the application site.



Stiff, matted hair or a damp, oily appearance of the hair may be observed at the application site on some ferrets. This is temporary and does not affect the safety and effectiveness of the product.

temporary and does not affect the safety and effectiveness of the product.

Heartworm Prevention: For prevention of heartworm disease, Advantage Multi for Cats should be administered at one-month intervals. Advantage Multi for Cats may be administered year-around or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer Advantage Multi for Cats immediately and resume the monthly dosing schedule.

Flea Treatment: For the treatment of flea infestations on ferrets, Advantage Multi for Cats should be administered at one-month intervals. If the ferret is already infested with fleas when the first dose of Advantage Multi for Cats is administered, adult fleas on the ferret will be killed. However, re-infestation from the emergence of pre-existing pupae in the environment may continue to occur for six weeks or longer after treatment is initiated.

## STORAGE INFORMATION:

Store at temperatures between 4°C (39°F) and 25°C (77°F), avoiding excess heat or cold.

HOW SUPPLIED:
Applications Per Package
3 x 0.23 mL tubes
6 x 0.4 mL tubes 6 x 0.8 mL tubes

Advantage Multi is protected by one or more of the following U.S. patents: 6,232,328 and 6,001,858

V-03/2016

NADA # 141-254, Approved by FDA

© 2015 Baver

Bayer, the Bayer Cross and Advantage Multi are registered trademarks of Bayer.



Bayer HealthCare LLC Animal Health Division P.O. Box 390 Shawnee Mission, Kansas 66201 U.S.A.